SERMs and aromatase inhibitors are used in infertile men without a clear hypogonadism due to gonadotropin deficiency and they produce an overstimulation of FSH-mediated mechanisms and increased testosterone concentration within the testis. This evidence concerns the gene BRD2 and hypogonadism.